These results support the future development of small-molecule drug-targeted inhibitors, antisense oligonucleotides or degraders (e.g., proteolysis targeting chimeras [PROTACs]) of CHAF1B for the treatment of patients with MPN, as an approach to enhance IFN sensitivity and overcome IFN resistance. Here, CHAF1B is linked to myeloproliferative neoplasm.